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Abstract
Background: The calcium-sensing receptor (CaSR) is a calcium (Ca2+) sensitive G protein-coupled receptor
implicated in various biological processes. In particular, it regulates Ca2+/Mg2+- homeostasis and senses interstitial
Ca2+ levels and thereby controls downstream signalling cascades. Due to its expression in the gut epithelium, the
enteric nervous system and smooth muscles and its key function in regulation and coordination of muscular
contraction and secretion, it represents an excellent candidate gene to be investigated in the pathophysiology of
irritable bowel syndrome (IBS). Disturbed CaSR structure and function may impact gastrointestinal regulation of
muscular contraction, neuronal excitation and secretion and consequently contribute to symptoms seen in IBS,
such as disordered defecation as well as disturbed gut motility and visceral sensitivity.
Methods: We have therefore genotyped the functional CASR SNP rs1801725 in three case control samples from the
UK, Belgium and the USA.
Results: Genotype frequencies showed no association in the three genotyped case–control samples, neither with
IBS nor with IBS subtypes.
Conclusions: Although we could not associate the SNP to any of the established bowel symptom based IBS
subtypes we cannot rule out association to altered Ca2+ levels and disturbed secretion and gut motility which were
unfortunately not assessed in the patients genotyped. This underlines the necessity of a more detailed phenotyping
of IBS patients and control individuals in future studies.
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Background
The calcium-sensing receptor (CaSR) is a multifunc-
tional G protein-coupled receptor implicated in vari-
ous biological processes [1, 2]. Besides its expression
in tissues maintaining systemic calcium/magnesium
(Ca2+/Mg2+) homeostasis such as parathyroid, thyroid
glands and the kidney, it can also be found in the
gastrointestinal (GI) tract. The receptors have been
detected in the gut epithelium from the stomach to
the small and large intestine [3, 4], as well as in the
plexus submucosus and plexus myentericus of the
enteric nervous system (ENS) [5] and in smooth
muscle cells [6]. To date, the CaSR has been shown
to be involved in the regulation of colonic secretion
[7, 8] and modulation of gut motility in response to
changes of interstitial Ca2+ levels [9–11]. Interestingly,
studies have shown that constipation in hyperparathyroid-
ism is associated with reduced neuromuscular excitability
as a result of increased interstitial Ca2+ levels [12]. This
was mediated by CaSRs on the myenteric plexus regulat-
ing smooth muscle function and coordination [10, 11].
Intestinal motility is modulated in a highly complex
manner with Ca2+ playing a fundamental role in regula-
tion of muscular contraction and neuronal excitation.
Contraction of smooth muscle cells is controlled by the
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interstitial Ca2+ levels and the sensitivity of the contractile
elements to Ca2+ in response to changes in the interstitial
space [13]. Activation of CaSRs causes Ca2+ release from
intracellular Ca2+ stores such as the endoplasmic reticulum
by initializing intracellular second messenger cascades and
consequently increasing interstitial Ca2+ levels [6, 14].
Consequently, a dysfunctional CaSR causing disturbed
intestinal Ca2+ absorption may have effects on intes-
tinal motility, secretion [7, 8], neuromuscular excit-
ability, colonic fluid transport, peptide release and
contribute to the symptoms seen in functional GI
disorders, such as Irritable Bowel Syndrome (IBS).
IBS patients present with abdominal pain associated
with a change in bowel habit [15]. Depending on
predominant bowel habit, IBS is further sub-typed into
IBS-C (constipation), IBS-D (diarrhea), IBS-M (mixed
constipation/ diarrhea) and IBS-U (unspecified) [16–21].
Despite intense research, its pathophysiology remains
unclear but is thought in part to be related to disordered
motility, secretion and visceral sensation. Dysfunction
within the ENS [22] and/or central nervous system, along
with impaired mucosal barrier function have all been
implicated in its pathophysiology [23].
Interestingly, a large meta-analysis including 12.865
individuals of European and Indian descent correlated
serum Ca2+ level with single nucleotide polymor-
phisms (SNPs) in the CASR gene [24]. In particular,
the minor allele of the CASR SNP rs1801725 was
reported to be strongly associated with increased
serum Ca2+ levels (p < 0.001). This SNP encodes a
missense variant which leads to a non-conservative
amino acid change: (c.2956 G > T, p.Ala986Ser = A986S)
residing in the cytoplasmic tail of the CaSR [24]. In vitro
studies showed that mutations within the respective
region of the receptor may influence CaSR function,
impair signal transduction, intracellular trafficking and/or
cell surface expression, respectively [25–27]. The func-
tions and influences of a dysfunctional CaSR have not
been explored in IBS previously. We hypothesized that
this common CASR polymorphism may be relevant in the
pathophysiology of IBS and evaluated rs1801725 in
patients with IBS from three case–control cohorts from
the UK, Belgium and the USA.
Methods
Genotyped study subjects
Case–control cohort from Manchester (UK)
SNP genotyping was performed in a cohort of 86
patients with IBS-D (aged 18–66 years; mean age
41.7 years; 60 female, 26 male), 88 with IBS-C (aged
18–65 years; mean age 39.9 years; 82 female, 6 male)
and 86 healthy controls (aged 18–63 years; mean age
35.0 years; 55 female, 31 male) (Table 1). IBS patients
with mixed bowel habit (IBS-M) were not included.
Recruitment of IBS patients was via the Out Patients
Departments of the University Hospital of South
Manchester, local general practices, advertisement in
regional newspapers and an existing departmental
volunteer pool of patients. All patients satisfied the
Rome II criteria for IBS and predominant bowel habit
subtype [28]. Moreover, they underwent appropriate
investigations to exclude organic disease [15] and did
not show any functional disorder of the upper GI tract
that was more prominent than their IBS. In addition,
no subject had a history of major psychiatric disorder
or history of alcohol or substance abuse. Healthy
controls were recruited by advertisement. All subjects
were Caucasian and drank below the recommended
safe alcohol limit (<21 units/week) smoked <5 cigarettes
per day. Written consent was obtained from all
subjects and the study was approved by the South
Manchester Medical Research Ethics Committee.
DNA was extracted from peripheral blood cells taken
from both the patients and healthy controls using
standard protocols [29].
Case–control cohort from St. Louis, Missouri (USA)
The second genotyped cohort included 28 patients with
IBS-D (aged 20–83 years; mean age 49.9 years; 18
female, 10 male), 16 IBS-C patients (aged 28–64 years;
mean age 45.9 years; 10 female, 6 male); and 86 healthy
controls (aged 18–81 years; mean age 55.9 years; 45
female, 41 male) (Table 1). IBS patients with mixed
bowel habit (IBS-M) were not included. The group was
composed of adult subjects (≥18 years old) who carried
a clinical functional GI disease (FGID) diagnosis, and
met Rome III criteria for IBS. Prior to enrolment in the
study, all FGID subjects had organic bowel disease
excluded with a comprehensive evaluation, including but
not limited to laboratory, endoscopic and radiographic
testing, performed at the discretion of the treating
gastroenterologist. The control group consisted of
patients undergoing screening endoscopy in the absence
of on going GI diagnoses or symptoms at the time
of enrolment, and without evidence for FGID using
Rome III criteria. All participants provided written
informed consent prior to collection of biological
specimens and clinical data. The study protocol was
approved by the Human Research Protection Office
(institutional review board) at Washington University
School of Medicine and Barnes-Jewish Hospital, St.
Louis, Missouri. Sputum and/or blood samples were
collected for DNA analysis at the time of subject
enrolment. Blood was collected in cases where the
participant was to undergo phlebotomy for clinical
purposes. If a blood specimen was not required for
other laboratory testing, a sputum sample was
collected. DNA was extracted using Qiagen Gentra
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Puregene Reagents (Qiagen Inc., Valencia, CA). Following
DNA extraction, samples were frozen and banked by the
Biobank Core of the Washington University Digestive
Diseases Research Center.
Case–control cohort from Leuven (Belgium, BEL)
The third genotyped cohort included 420 patients with
IBS-D (aged 18–83 years; mean age 41.0 years; 305
female, 115 male), 313 IBS-C patients (aged 18–82 years;
mean age 43.6 years; 288 female, 25 male) and 622
healthy controls (aged 18–82 years; mean age 43.5 years;
470 female, 152 male) (Table 1). IBS patients with mixed
bowel habit (IBS-M) were not included. Further details
can be found in Wouters et al. [30].
Genotyping
The SNP genotyping was performed with the KASPar®
assay system (KBiosciences, Ltd, Hoddesdon, UK) as
recommended by the manufacturer using a custom-
ized assay. An initial 15-min cycle at 94 °C was
followed by 20 cycles consisting of 10 s at 94 °C, 5 s at
57 °C, and 10 s at 72 °C; 28 cycles consisting of 10 s at
94 °C, 20 s at 57 °C, and 40 s at 72 °C; and a cool
down at 10 °C. After the thermal cycling, KASPar®
analysis was performed using the fluorescence plate
reader TaqMan7500 system (Applied Biosystems,
Foster City, CA).
Statistical analysis
Chi-squared tests were used to assess deviations of
observed genotype frequencies from Hardy-Weinberg-
Equilibrium (HWE). Genotype relative risks of IBS were
quantified by odds ratios (ORs) with corresponding
95 % confidence intervals (CIs) based on a logistic
regression model under additive genetic penetrance.
Tests for deviation from Hardy-Weinberg equilibrium and
tests for association were performed using an online tool
provided by the Institute of Human Genetics, Technical
University of Munich (http://ihg.gsf.de/cgi-bin/hw/
hwa1.pl). In addition, results were stratified by IBS
subtypes. Probability values were adjusted for multipli-
city using the Holm-Bonferroni method.
Results
In our study we analyzed the SNP rs1801725 (p. A986S)
of the CASR gene, which has not been examined in IBS
previously. We investigated three case–control samples
with 1745 individuals of Caucasian origin (Table 1). Geno-
type frequencies did not deviate from Hardy-Weinberg
equilibrium and showed no association in the three
genotyped case–control samples, neither with IBS
nor with IBS subtypes (Table 2). In addition, no sig-
nificant differences between the three case–control
cohorts could be identified.
Discussion
This is the first study to investigate whether the
CASR SNP rs1801725 associates with the functional
GI disorder IBS. The investigated SNP is known to
be associated with increased serum Ca2+ levels [24]
and has therefore a potentially inactivating effect on
the CaSR. The set point (= onset of activation) is
increased for inactivating mutations or polymor-
phisms compared to CASR wild-type. For receptor
activation, the concentration of the CaSR agonist
Ca2+ needs to be higher in comparison to the CaSR
wild-type. Consequently, with respect to intestinal
motility, an increased frequency of the CASR p.986S
Table 1 Characteristics of the genotyped case–control cohorts
case–control cohort IBS patients Sex Age IBS-C patients IBS-D patients healthy volunteers Sex Age
UK 174 ♀142 ♂32 18-66 years
ø 40.8 years
88 86 86 ♀55 ♂31 18-63 years
ø 35.0 years
USA 44 ♀28 ♂16 20-83 years
ø 47.9 years
16 28 86 ♀45 ♂41 18-81 years
ø 55.9 years
BEL 733 ♀593 ♂140 18-83 years
ø 42.3 years
313 420 622 ♀470 ♂152 18-82 years
ø 43.5 years
Total 951 ♀819 ♂200 18-83 years
ø 43.6 years
417 534 794 ♀570 ♂224 18-82 years
ø 44.8 years
Table 2 Genotyping data for CASR p. A986S (rs1801725) in the three case–control cohorts
IBS IBS-C IBS-D
case–control cohort SNP OR (95 % CI) Holm-Bonferroni adjusted P-value P-value HWE OR (95 % CI) OR (95 % CI)
Total rs1801725 0.95 (0.81-1.19) 0.85 0.49 0.97 (0.79-1.29) 0.92 (0.76-1.20)
UK rs1801725 1.257 (0.67-1.93) 0.63 0.23 1.041 (0.54-1.811) 1.481 (0.726-2.37)
USA rs1801725 1.12 (0.51-2.92) 0.65 0.3 1.122 (0.32-3.22) 0.851 (0.25-1.96)
BEL rs1801725 1.014 (0.78-1.21) 0.84 1.0 1.015 (0.74-1.29) 1.013 (0.76-1.25)
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allele in the IBS-D group compared to control indi-
viduals would be conceivable. Although our study
showed no association overall or in any of the three
genotyped cohorts or with respect to the established
bowel symptom based IBS-subtypes, association to
changed motility and transit cannot be excluded. In
fact, disturbances in the motility of the GI tract have
been shown to be an important feature of IBS, with
these varying with sub-type studied. In this sense,
IBS-D patients have been shown to have increased
colonic motility, particularly high amplitude propa-
gating contractions (HAPCs) and accelerated transit
[31]. In contrast, IBS-C patients exhibit reduced
motility, less HAPCs and slower transit compared
with healthy volunteers [32]. Furthermore, IBS-D
patients presented with an increased basal motility
index (contractions per minute) compared to patients
with IBS-C [33]. Although in general these various motor
patterns associate with a particular sub-type of IBS,
not all IBS patients in those subtypes will exhibit
them. Stratification for any of these traits would have
increased the likelihood to correlate a functional SNP
with in a particular subset of patients. However, add-
itional analysis stratifying for total serum Ca2+ levels,
disturbed motility or secretion were not possible since
this data were lacking. This underlines the importance
of a more detailed patient characterization and assess-
ment of relevant traits and laboratory parameters.
Colonic motility for example could be assessed by
oroanal transit time measurement [34, 35]. Stool scale
form could be taken into account as measure for
transit time implementing the Bristol Stool Scale into
the phenotyping pipeline of the patients and control
individuals [36].
Conclusions
Although we could not associate the SNP to any of the
established bowel symptom based IBS subtypes we can-
not rule out association to altered Ca 2+ levels and gut
motility which were unfortunately not assessed in the
patients genotyped. Further investigation of CASR-re-
lated genetic variations in IBS and relevant intermediate
traits such as Ca2+ serum levels in addition to the assess-
ment of motility, transit and secretion are needed for a
detailed characterization of the gene function and a bet-
ter understanding of the correlation between CASR vari-
ants and the aetiology of IBS.
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